Last reviewed · How we verify
NCT05566002: AIPHY
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
trial testing Right heart catheterization in Pulmonary Hypertension in 2,000 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Chinese Pulmonary Vascular Disease Research Group |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 June 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Right heart catheterization
Conditions studied
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
- Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →
Sponsor
Chinese Pulmonary Vascular Disease Research Group
Who can join
18 and older, any sex, with Pulmonary Hypertension or Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Development and validation of multimodal deep learning algorithms for detecting pulmonary hypertension.
Zhao W, Huang Z, Diao X, Yang Z, et al · · 2025 · cited 7× · PMID 40205021 · DOI 10.1038/s41746-025-01593-3 -
Deep Learning-Enhanced Noninvasive Detection of Pulmonary Hypertension and Subtypes via Chest Radiographs, Validated by Catheterization.
Huang Z, Diao X, Huo Y, Zhao Z, et al · · 2025 · cited 3× · PMID 40541737 · DOI 10.1016/j.chest.2025.06.008
Verify or expand the search:
- PubMed search for NCT05566002
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Right heart catheterization
Trials testing the same drug.
- NCT05851872 — Fasting Versus Non-fasting on Outcomes and Satisfaction Prior to Cardiac Catheterization · NA · completed
- NCT05575557 — Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment · NA · unknown
- NCT04970953 — Diastolic Exercise Stress Testing in Heart Failure · terminated
- NCT03089164 — Postural Changes During Right Heart Catheterization · terminated
- NCT06023134 — Clinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure · active not recruiting
Other recruiting trials for Pulmonary Hypertension
Currently open trials in the same condition.
- NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
- NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
- NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting
Other Chinese Pulmonary Vascular Disease Research Group trials
Trials by the same sponsor.
- NCT07481877 — Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study · not yet recruiting
- NCT05569655 — Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH · NA · unknown
- NCT05553015 — A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH) · unknown
- NCT05595200 — Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension · unknown
- NCT06135909 — CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05566002 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Pulmonary Vascular Disease Research Group
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05566002.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing